Drug intelligence / Profile preview

AUTEN-67

Development stage: Preclinical
Lead developer: Velgene Biotechnology
Modality: Small Molecules
Administration: Oral

Overview

AUTEN-67 is a drug that functions as an inhibitor of the enzymatic activity of Myotubularin-related protein 3 (MTMR3). It has been shown to inhibit MTMR3 enzymatic activity at a concentration of 100μM and to reduce CpG-induced IgA production by 34%. This mechanism suggests its potential as a therapeutic agent for conditions characterized by elevated IgA levels, such as IgA nephropathy, by modulating the TLR9–TRAF3–IFN-β axis.

Targets

MTMR14 (Myotubularin-related protein 14)

Beyond the preview

Go deeper on AUTEN-67.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AUTEN-67.

Explore the full profile